Skip to content
Medical Health Aged Care

‘Patient safety must come first’: GPs urge patients to consult with their regular GP

Royal Australian College of GPs 2 mins read

Victorian GPs are urging patients to consult with their regular GP, rather than going to a chemist for a “quick fix” that may not address the real problem. 

It comes following the state’s Health Department launching a media campaign for pharmacy prescribing. 

Royal Australian College of GPs (RACGP) Victoria Chair Dr Anita Muñoz encouraged patients to seek care from a GP who knows them, and this history 

“Patient safety must come first,” she said. 

“We’re urging people to see a GP for a diagnosis because there is no such thing as a ‘simple’ health condition, and pharmacists are not trained to diagnose. GPs spend over a decade training including practising under supervision for many years to diagnose a myriad of health conditions. 

“This program is allowing pharmacists to hand out medicines, including antibiotics, based off checklists and flowcharts after a short online course – this cannot replace a medical diagnosis, and patients accessing these services from chemists need to know that. 

“Removing the GP diagnosis presents significant risks to patient safety, including incorrect treatment, delayed diagnosis, serious illnesses being missed, and increasing antimicrobial resistance, which will cost the health system more in the long term.  

“There are numerous reports of misdiagnosis and incorrect treatment from pharmacist prescribing programs in Queensland and New South Wales, and we fear we will see the same in Victoria. The pilot report showed of the patients who sought treatment for urinary tract infections symptoms in Victoria, 13% did not resolve. 

“We know the pharmacy lobby is pursuing a risky widespread pharmacy prescribing agenda across Australia, and they are ignoring the medical experts, and supressing debate. As a GP practising in Melbourne, it is deeply concerning and frustrating to see Victoria succumbing.” 

The College Victoria Chair said that high-quality patient care must always be paramount and warned that the community pharmacy program removes a key safeguard by supporting pharmacists to both prescribe and dispense medicine. 

“This is a fundamental conflict of interest. We’ve already seen the risks of prioritising profit in the telehealth space, and it is critical that these mistakes are not repeated in the rollout of pharmacy prescribing,” she said. 

"We will continue to advocate for a model that prioritises patient health and safety over shortcuts. The best care for patients is collaborative, and we need more government support for multidisciplinary models of care.  

“GPs and pharmacists each bring vital expertise to the healthcare system, and GPs value the work of pharmacists in all corners of the country. We back sensible measures such as funding for practices to add more pharmacists as part of a collaborative GP-led multidisciplinary care approach.”  

~ENDS 

RACGP spokespeople are available for interviews: 03 8699 0992 / [email protected]. 

 


About us:

About the RACGP  

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians. Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here 


Contact details:

Media team: 03 8699 0992 / [email protected]   

Follow us on Twitter: @RACGP and Facebook.  

More from this category

  • Medical Health Aged Care
  • 02/03/2026
  • 23:11
SBC Medical Group Holdings Incorporated

SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure

IRVINE, Calif.–BUSINESS WIRE– SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services…

  • Contains:
  • Medical Health Aged Care
  • 02/03/2026
  • 18:11
Takeda Pharmaceutical Company Limited

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE StudiesPrescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--BUSINESS WIRE-- Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted…

  • Medical Health Aged Care
  • 02/03/2026
  • 13:04
Alexion, AstraZeneca Rare Disease

Ultomiris® now available on the PBS for Australians living with generalised myasthenia gravis

Alexion, AstraZeneca Rare Disease’s Ultomiris® (ravulizumab rch) has been listed on the Pharmaceutical Benefits Scheme (PBS) for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive (Ab+). The Minister for Health and Ageing, The Hon Mark Butler MP, made the announcement at today’s World Rare Disease Day event at Parliament House. Ultomiris is now available on the PBS for people with acute, severe gMG at high risk of rapid deterioration; for short term disease control as other treatments take effect; and for people not responding, intolerant or contraindicated to other therapies.[1],[2] gMG is a rare, debilitating,…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.